Back to top

Is GW Pharmaceuticals (GWPH) Outperforming Other Medical Stocks This Year?

Read MoreHide Full Article

Investors interested in Medical stocks should always be looking to find the best-performing companies in the group. Has GW Pharmaceuticals (GWPH - Free Report) been one of those stocks this year? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.

GW Pharmaceuticals is one of 867 companies in the Medical group. The Medical group currently sits at #3 within the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.

The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. GWPH is currently sporting a Zacks Rank of #1 (Strong Buy).

Over the past three months, the Zacks Consensus Estimate for GWPH's full-year earnings has moved 42.84% higher. This shows that analyst sentiment has improved and the company's earnings outlook is stronger.

Based on the latest available data, GWPH has gained about 38.53% so far this year. Meanwhile, the Medical sector has returned an average of 3.26% on a year-to-date basis. This shows that GW Pharmaceuticals is outperforming its peers so far this year.

Breaking things down more, GWPH is a member of the Medical - Products industry, which includes 80 individual companies and currently sits at #75 in the Zacks Industry Rank. On average, this group has gained an average of 17.81% so far this year, meaning that GWPH is performing better in terms of year-to-date returns.

Going forward, investors interested in Medical stocks should continue to pay close attention to GWPH as it looks to continue its solid performance.


In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


GW Pharmaceuticals PLC (GWPH) - free report >>

Published in